Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Anthony John Iafrate, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Anthony Iafrate and Dora Dias-Santagata.
Connection Strength

4.008
  1. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010 May; 2(5):146-58.
    View in: PubMed
    Score: 0.448
  2. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 08; 11(8):1242-1245.
    View in: PubMed
    Score: 0.171
  3. Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy. J Mol Diagn. 2016 Jan; 18(1):124-30.
    View in: PubMed
    Score: 0.164
  4. Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol Oncol. 2014 Jul; 8(5):859-73.
    View in: PubMed
    Score: 0.147
  5. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90.
    View in: PubMed
    Score: 0.134
  6. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
    View in: PubMed
    Score: 0.131
  7. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 01; 18(5):1227-36.
    View in: PubMed
    Score: 0.126
  8. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17(1):72-9.
    View in: PubMed
    Score: 0.125
  9. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
    View in: PubMed
    Score: 0.124
  10. Mutational analysis and clinical correlation of 185 consecutive metastatic colorectal patients: Similarities and differences between colon and rectal patients. J Clin Oncol. 2011 May 20; 29(15_suppl):3536.
    View in: PubMed
    Score: 0.120
  11. Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. J Clin Oncol. 2011 May 20; 29(15_suppl):5579.
    View in: PubMed
    Score: 0.120
  12. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948.
    View in: PubMed
    Score: 0.119
  13. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Mod Pathol. 2011 Jul; 24(7):974-82.
    View in: PubMed
    Score: 0.119
  14. t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv. 2021 Sep 29.
    View in: PubMed
    Score: 0.062
  15. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 04 15; 26(8):1877-1885.
    View in: PubMed
    Score: 0.055
  16. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Dec; 25(12):1949.
    View in: PubMed
    Score: 0.054
  17. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 09; 25(9):1415-1421.
    View in: PubMed
    Score: 0.054
  18. Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. Hum Pathol. 2019 11; 93:65-73.
    View in: PubMed
    Score: 0.053
  19. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol Commun. 2019 04 29; 7(1):66.
    View in: PubMed
    Score: 0.052
  20. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387.
    View in: PubMed
    Score: 0.052
  21. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist. 2019 10; 24(10):1356-1367.
    View in: PubMed
    Score: 0.052
  22. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol. 2019 04; 86:1-11.
    View in: PubMed
    Score: 0.051
  23. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.050
  24. Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell. 2018 08 13; 34(2):242-255.e5.
    View in: PubMed
    Score: 0.050
  25. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.049
  26. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.049
  27. Artificial Intelligence Approach for Variant Reporting. JCO Clin Cancer Inform. 2018; 2.
    View in: PubMed
    Score: 0.048
  28. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov. 2018 04; 8(4):417-427.
    View in: PubMed
    Score: 0.048
  29. Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.047
  30. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5.
    View in: PubMed
    Score: 0.045
  31. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
    View in: PubMed
    Score: 0.043
  32. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. Int J Colorectal Dis. 2016 05; 31(5):973-982.
    View in: PubMed
    Score: 0.042
  33. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn. 2015 Nov; 17(6):661-8.
    View in: PubMed
    Score: 0.040
  34. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointest Endosc. 2016 Jan; 83(1):140-8.
    View in: PubMed
    Score: 0.040
  35. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May; 10(5):768-777.
    View in: PubMed
    Score: 0.040
  36. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov. 2015 Jul; 5(7):713-22.
    View in: PubMed
    Score: 0.040
  37. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015 Apr; 5(4):358-67.
    View in: PubMed
    Score: 0.039
  38. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014 Sep; 9(9):1363-9.
    View in: PubMed
    Score: 0.038
  39. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014 Nov; 99(11):E2457-62.
    View in: PubMed
    Score: 0.038
  40. Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis. Int J Chron Obstruct Pulmon Dis. 2014; 9:525-31.
    View in: PubMed
    Score: 0.037
  41. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909.
    View in: PubMed
    Score: 0.037
  42. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014 May 15; 120(10):1482-90.
    View in: PubMed
    Score: 0.036
  43. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77.
    View in: PubMed
    Score: 0.036
  44. Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. J Clin Oncol. 2013 Sep 10; 31(26_suppl):145.
    View in: PubMed
    Score: 0.035
  45. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4273-81.
    View in: PubMed
    Score: 0.035
  46. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol. 2013 May 10; 31(14):e233-6.
    View in: PubMed
    Score: 0.034
  47. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol. 2013 Feb; 37(2):287-94.
    View in: PubMed
    Score: 0.034
  48. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS One. 2012; 7(10):e47290.
    View in: PubMed
    Score: 0.033
  49. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 2012 Sep 20; 120(12):2395-404.
    View in: PubMed
    Score: 0.033
  50. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 2012 Nov; 25(11):1462-72.
    View in: PubMed
    Score: 0.032
  51. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 2012; 7(4):e35309.
    View in: PubMed
    Score: 0.032
  52. SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518.
    View in: PubMed
    Score: 0.030
  53. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol. 2011 Sep; 24(9):1177-90.
    View in: PubMed
    Score: 0.030
  54. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26.
    View in: PubMed
    Score: 0.030
  55. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol. 2011 Feb; 70(2):110-5.
    View in: PubMed
    Score: 0.029
  56. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011 Jan; 13(1):74-84.
    View in: PubMed
    Score: 0.029
  57. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011 Apr; 121(1):212-7.
    View in: PubMed
    Score: 0.029
  58. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010 Nov 23; 3(149):ra84.
    View in: PubMed
    Score: 0.029
  59. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010 Sep; 19(3):157-63.
    View in: PubMed
    Score: 0.029
  60. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010 Jan 19; 17(1):77-88.
    View in: PubMed
    Score: 0.027
  61. Uterine tumors resembling ovarian sex cord tumors (UTROSCT) lack the JAZF1-JJAZ1 translocation frequently seen in endometrial stromal tumors. Am J Surg Pathol. 2009 Aug; 33(8):1206-12.
    View in: PubMed
    Score: 0.027
  62. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol. 2008 Nov; 111(2):289-97.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.